PMID- 35729340
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20220812
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 9
DP  - 2022 Sep
TI  - Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in 
      patients with acute migraine: a systematic review and meta-analysis.
PG  - 1365-1376
LID - 10.1007/s00228-022-03347-6 [doi]
AB  - OBJECTIVE: Calcitonin gene-related peptide (CGRP) receptor antagonists have been 
      suggested as novel treatments for acute migraine. This study aimed to use 
      meta-analysis to compare the safety and tolerability of five existing oral CGRP 
      receptor antagonists (BI44370TA, MK-3207, rimegepant, telcagepant, and 
      ubrogepant) with that of a placebo or triptans against acute migraine. METHODS: 
      Five prominent databases were searched to identify randomized controlled trials 
      on this topic. The primary safety outcomes of interest were any adverse events 
      (AEs) and treatment-related adverse events (TRAEs), and secondary outcomes were 
      individual events, namely diarrhea, dizziness, dry mouth, fatigue, nausea, 
      paresthesia, somnolence, upper abdominal pain, and vomiting. RESULTS: Fifteen 
      studies met the eligibility criteria and were examined in detail. Although, 
      compared to placebo, oral CGRP receptor antagonists significantly increased the 
      incidence of any AEs (risk ratio [RR] = 1.15; 95% confidence interval 
      [CI] = 1.07-1.23), there was no difference in the incidence of TRAEs (RR = 1.18; 
      95% CI = 1.00-1.38). Moreover, CGRP receptor antagonists were safer than triptans 
      with respect to primary safety outcomes, such as any AEs (RR = 0.78; 95% 
      CI = 0.63-0.98) and TRAEs (RR = 0.68; 95% CI = 0.58-0.79). CONCLUSION: Despite 
      oral CGRP receptor antagonists posing a significantly higher risk of AEs when 
      compared to placebo, CGRP receptor antagonists have a favorable safety profile 
      compared to triptans. Our findings inform strategies to enhance safety and 
      tolerability in the treatment of acute migraine.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Lee, Seoyeon
AU  - Lee S
AD  - College of Pharmacy, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, 
      Republic of Korea.
AD  - Department of Pharmacy, Seoul National University Bundang Hospital, 166 Gumi-ro, 
      Bundang-Gu, Seongnam-Si, Gyeonggi-Do, 13620, Republic of Korea.
FAU - Staatz, Christine E
AU  - Staatz CE
AUID- ORCID: 0000-0002-4595-9376
AD  - School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of 
      Queensland, 20 Cornwall St, Woolloongabba, QLD, 4102, Brisbane, Australia.
FAU - Han, Nayoung
AU  - Han N
AUID- ORCID: 0000-0003-4796-8564
AD  - College of Pharmacy, Jeju National University, 102 Jejudaehak-ro, Jeju, 63241, 
      Republic of Korea. hanny@jejunu.ac.kr.
FAU - Baek, In-Hwan
AU  - Baek IH
AUID- ORCID: 0000-0002-9538-0565
AD  - College of Pharmacy, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, 
      Republic of Korea. baek@ks.ac.kr.
LA  - eng
GR  - 2021011/Kyungsung University Research Grants/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220622
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Calcitonin Gene-Related Peptide Receptor Antagonists)
RN  - 0 (Receptors, Peptide)
RN  - 0 (Tryptamines)
RN  - 9007-12-9 (Calcitonin)
SB  - IM
MH  - Calcitonin/therapeutic use
MH  - *Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects
MH  - Humans
MH  - *Migraine Disorders/drug therapy
MH  - Receptors, Peptide/therapeutic use
MH  - Tryptamines/adverse effects
OTO - NOTNLM
OT  - Calcitonin gene-related peptide receptor antagonists
OT  - Meta-analysis
OT  - Migraine
OT  - Safety
OT  - Triptan
EDAT- 2022/06/22 06:00
MHDA- 2022/08/13 06:00
CRDT- 2022/06/21 23:29
PHST- 2022/03/17 00:00 [received]
PHST- 2022/05/29 00:00 [accepted]
PHST- 2022/06/22 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2022/06/21 23:29 [entrez]
AID - 10.1007/s00228-022-03347-6 [pii]
AID - 10.1007/s00228-022-03347-6 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Sep;78(9):1365-1376. doi: 10.1007/s00228-022-03347-6. 
      Epub 2022 Jun 22.